☆ 4.7 Article

The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial

DIABETES OBESITY & METABOLISM (2023)

Related references

Note: Only part of the references are listed.

Article Endocrinology & Metabolism

Quetelet (body mass) index and effects of dapagliflozin in chronic kidney disease

Glenn M. Chertow et al.

Summary: This study aimed to assess the effects of dapagliflozin in patients with chronic kidney disease and albuminuria, with and without type 2 diabetes, stratified by BMI. The results showed that dapagliflozin had kidney and cardiovascular benefits across different BMI categories.

DIABETES OBESITY & METABOLISM (2022)

Add to Collection

Article Endocrinology & Metabolism

SGLT inhibitors on weight and body mass: A meta-analysis of 116 randomized-controlled trials

Alex Jia Yang Cheong et al.

Summary: This meta-analysis confirms the weight reduction benefits of SGLT inhibitors and indicates that SGLT1/SGLT2 inhibitors are more effective in reducing weight. However, further studies are needed to clarify their role in weight management.

OBESITY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

Kazuma Oyama et al.

Summary: The study investigated the associations between obesity, cardiorenal events, and the benefits of dapagliflozin in patients with type 2 diabetes mellitus. The results showed that higher BMI was associated with a higher risk of heart failure and atrial fibrillation. Dapagliflozin reduced body weight consistently across BMI categories, and obese patients tended to derive greater absolute risk reduction in heart failure and atrial fibrillation.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dapagliflozin for heart failure according to body mass index: the DELIVER trial

Carly Adamson et al.

Summary: Obesity is common in HFpEF patients and is associated with higher rates of heart failure hospitalization and worse health status. Treatment with dapagliflozin improves cardiovascular outcomes across the spectrum of BMI, leads to greater symptom improvement in patients with obesity, compared with those without, and has the additional benefit of causing modest weight loss.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Article Urology & Nephrology

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

Brendon L. Neuen et al.

Summary: The study showed that canagliflozin has consistent relative effects across different KDIGO risk categories, but the absolute risk reductions are likely greater in higher risk categories. The KDIGO classification system may help identify individuals who could benefit more from treatment with canagliflozin for organ protection.

AMERICAN JOURNAL OF KIDNEY DISEASES (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease Insights From the CREDENCE Trial

Nan Ye et al.

Summary: The study demonstrates that canagliflozin lowers systolic blood pressure in patients with type 2 diabetes and chronic kidney disease, reduces the need for additional blood pressure-lowering agents, and shows consistent effects across various systolic blood pressure levels and antihypertensive therapy subgroups.

CIRCULATION (2021)

Add to Collection

Article Endocrinology & Metabolism

Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia

Qiuhe Ji et al.

Summary: Empagliflozin reduces cardiorenal and mortality risk regardless of baseline BMI, including in Asians.

DIABETES OBESITY & METABOLISM (2021)

Add to Collection

Article Endocrinology & Metabolism

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

Toshiaki Ohkuma et al.

DIABETES OBESITY & METABOLISM (2020)

Add to Collection

Article Pharmacology & Pharmacy

Impact of gastrointestinal physiology on drug absorption in special populations – An UNGAP review

Cordula Stillhart et al.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

V. Perkovic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Urology & Nephrology

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program

Brendon L. Neuen et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters

Cornelis Smit et al.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)

Add to Collection

Review Urology & Nephrology

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

Lennart Tonneijck et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Urology & Nephrology

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

Meg J. Jardine et al.

AMERICAN JOURNAL OF NEPHROLOGY (2017)

Add to Collection

Article Endocrinology & Metabolism

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial

Bruce Neal et al.

DIABETES OBESITY & METABOLISM (2017)

Add to Collection

Review Physiology

Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus

Muhammad A. Abdul-Ghani et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial

Bruce Neal et al.

AMERICAN HEART JOURNAL (2013)

Add to Collection

Article Endocrinology & Metabolism

The magnitude of association between overweight and obesity and the risk of diabetes: A meta-analysis of prospective cohort studies

Asnawi Abdullah et al.

DIABETES RESEARCH AND CLINICAL PRACTICE (2010)

Add to Collection

Article Nutrition & Dietetics

Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults

Katherine M. Flegal et al.

AMERICAN JOURNAL OF CLINICAL NUTRITION (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.